GlassScriptPhysician profile
Andrew Rego
NPI 1649644477
$3,513.95
in general payments reported to CMS, 2019-2025
23 companies · $666 in 2025
The $666 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $495 · 2023: $1,197 · 2024: $954 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $552.54 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $498.25 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $415.40 | 2021-2025 | |
| Abbott Laboratories | $307.57 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $225.91 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $225.51 | 2023-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $220.84 | 2021-2023 | Trintellix, Vpriv |
| Pfizer INC. | $208.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.34 | 2021-2024 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $135.42 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $98.25 | 2023 | Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.40 | 2021-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $72.93 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $47.07 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $38.63 | 2022-2023 | Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $37.84 | 2022-2023 | Gvoke Hypopen |
| Insightec,INC | $32.43 | 2025 | Exablate |
| Indivior INC. | $32.00 | 2021 | |
| Corcept Therapeutics | $29.14 | 2024 | Korlym |
| Idorsia Pharmaceuticals US INC | $18.47 | 2023 | Quviviq |
| Alkermes, INC. | $16.29 | 2023 | Vivitrol |
| Echosens North America, INC. | $14.72 | 2025 | Fibroscan |
| Merck Sharp & Dohme LLC | $14.06 | 2023 | Gardasil 9, M-M-R II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.